The ultimate goal of paediatric oncology is to provide cure at least cost to the child. Nowhere is this truer than for those children who undergo the most intensive therapy, including BMT. Long-term effects for these children are therefore of great importance, and have been the subject of recent review in the journal. 1 Over 50% of children presenting with AML can now expect to be cured. 2, 3 The majority of these children have received intensive chemotherapy, often including high-dose chemotherapy prior to BMT. In the past, many of these children received total body irradiation (TBI) as part of their BMT treatment. There is no doubt that TBI impairs growth, puberty and fertility in many patients. 1 Recent reports have described outcome in children transplanted using busulfan as a substitute for TBI. However, Correspondence: Dr PJ Shaw, Oncology Unit, New Children's Hospital, Westmead, NSW 2145, Australia Received 26 April 1999; accepted 30 January 2000 these studies are limited by short follow-up, the inclusion of patients who had received cranial irradiation as part of treatment and often have a non-homogeneous patient population. [4] [5] [6] [7] We have previously reported the outcome of children with AML treated on a uniform protocol followed by allogeneic or autologous BMT. 3 This group of patients has been under regular follow-up for up to 10 years following BMT. The results of the longitudinal study of this group of patients are reported here. Furthermore, this patient population is unique in that they have been conditioned for transplant with busulfan given as a single daily dose, thus achieving a high systemic exposure but also very high peak busulfan levels. 
Patients and methods
Between May 1987 and March 1995, treatment was initiated in 48 children with a primary diagnosis of AML. Results of initial therapy, transplant conditioning and outcome have already been presented for most of this group. 3 Since mid-1992, patients received idarubicin instead of daunorubicin. Twenty-three patients with AML were included in the study. Of 48 treated for AML in the study period, nine patients were excluded either because they transferred to another centre (n = 4) or did not undergo BMT (n = 5). Of 39 undergoing BMT, two patients with trisomy 21 are not considered here because of their different growth and endocrine potential, 9 and 14 patients died from relapse (n = 11) or transplant-related complications (n = 3).
Of the 23 study patients, none had CNS disease or received cranial irradiation. One child underwent testicular irradiation and bilateral orchiectomy following combined bone marrow and testicular relapse. Fifteen had autologous and eight a matched sibling BMT. There were 15 boys and eight girls with a median age of 10.88 years at the time of BMT (range 1.03-15.04 years). The median interval between diagnosis and BMT was 0.54 years (range 0.32-0.81 years). Duration from BMT to last follow-up assessment ranged from 2.01 to 9.98 years (median 4.9 years). Of the allogeneic recipients, all had matched sibling donors and all except one ceased cyclosporin by day +90.
10 None developed chronic graft-versus-host disease (GVHD). Transplant conditioning was with BU 150 mg/m 2 p.o. as a single daily dose for 4 days (total 600 mg/m 2 ) followed by CY 60 mg/kg once daily i.v. on days 5 and 6 (total 120 mg/kg). After BMT, all patients are offered regular followup in a specific BMT clinic as well as continued followup in a Late-Effects Clinic. At these clinics, auxological and endocrine data are collected, as well as dental, echocardiographic, respiratory and ophthalmological review. The results of growth and endocrine assessment are reported here.
Height determinations
Growth was assessed by height (Ht) measurement at diagnosis, at the time of BMT and yearly thereafter. Heights were taken for each patient using a Harpenden stadiometer. For patients less than 2 years old, length was measured supine. Height measurements were converted to HtSDS standardised for age and sex using the reference standards of Hamill et al. 11 The cumulative change in HtSDS (⌬HtSDS) at any given time was defined as the HtSDS at the time minus the SDS determined at the time of transplant.
Assessment of pubertal status
This was assessed clinically by the method of Tanner and Whitehouse. 12 Patients were considered assessable for puberty if they underwent BMT before the onset of or during early pubertal development.
Endocrine testing
Endocrine function tests included determination for thyroid function, insulin-like growth factor I (IGF-I), gonadotrophins, oestradiol in girls and testosterone in boys. The following assays were used: TSH (Corning Magic Mab Radioimmunoassay (RIA), Boston, MA, USA); free thyroxine (Vidas analyser of Bio-Merieux Marcy L'Etoile, France); IGF-I (Somatomedin-C RIA kit, Bioclone, NSW, Australia); LH (time-resolved fluoroimmunoassay kit, Wallac, Turku, Finland); FSH (time-resolved fluoroimmunoassay kit, Wallac); testosterone (in-house RIA at the Endocrinology laboratory, RAHC, using the testosterone tracer, TRK 921, Amersham, LifeScience, Buckinghamshire, UK, testosterone antiserum, T3-125, Endocrine Science, Clabasas, CA, USA, and standard solutions of testosterone from Steraloids, NH, USA); oestrogen (RIA kit by Sorin, Biomedica, Saluggia, Italy).
Statistical methods
The mean HtSDS of the entire group was calculated at diagnosis, BMT and at yearly follow-up post BMT. HtSDS of the group was expressed as mean Ϯ standard error of the mean (SEM). The HtSDS at BMT was compared with the scores at each of these points by paired t-test.
Pearson's correlation was used to examine the relation between two variables. The tests were performed using SPSS statistical software package version 6.1.4.
Results

Growth
Two patients had a HtSDS more than 2SD below normal at BMT; they also had a HtSDS more than 2SD below normal at the time of initial diagnosis (patients 9 and 22). The mean HtSDS for the group at yearly intervals, with 95% confidence intervals, is shown in Figure 1 . The estimated mean HtSDS for the entire group at BMT was −0.38 Ϯ 0.28, significantly different from HtSDS at initial diagnosis (−0.01 Ϯ 0.25, P = 0.001). There was no significant difference in HtSDS at yearly follow-up from 1-5 years compared to HtSDS at BMT.
Because of the significant difference in HtSDS from diagnosis to BMT, there was a significant difference from diagnosis to 1 to 4 years post BMT. However, this effect disappeared by 5 years post BMT, where there was no significant difference in HtSDS from diagnosis or from BMT to 5 years post BMT. This was found for the whole group and for boys alone (insufficient data for girls at 5 years to analyse).
Change in HtSDS (⌬HtSDS)
⌬HtSDS was calculated as the mean cumulative change in mean HtSDS between BMT and the following points: diagnosis and yearly after BMT for 5 years. ⌬HtSDS at these points were −0.37, 0.11, 0.07, −0.17, 0.20, 0.11, respectively.
Overall, there was no correlation between age at BMT and ⌬HtSDS. There was an inverse correlation between age at BMT and ⌬HtSDS (r 2 = 0.24, P = 0.04) at 1 year post BMT, but this was accounted for by two of the three youngest patients (Nos 9 and 14), who had an apparent ⌬HtSDS of +1.77 and +1.24, respectively, from BMT to 1 year post BMT. With exclusion of these two patients, the correlation between age at BMT and ⌬HtSDS disappeared. 
Final height and midparental Ht
Midparental HT was available for five patients who had attained or were near to their final Ht. These five patients had a mean height of 171.1 cm and a mean midparental Ht of 172.4 cm. Tables 1 and 2 detail age at BMT, age at last follow-up and the most recent endocrine and pubertal status of the 23 patients. Most patients had serial assessments of all parameters. Two patients refused formal follow-up and one returned for limited follow-up. Serial gonadotrophins for the eight female patients are shown in Table 3 . Of the eight females, two were pubertal at the time of BMT and two remain prepubertal. Four have had spontaneous puberty. All eight have had elevated gonadotropins post transplant. Five of the six older girls are on sex steroid replacement. Levels of LH and FSH have not necessarily returned into the normal range, as low dose replacement is being used. One has normal oestradiol levels Table 2 Endocrine and gonadal function in girls (n = Of the 15 boys, one was pubertal at BMT, seven have had a spontaneous puberty, one is in early puberty and one has required hormone replacement because of orchidectomy. Six of the seven who have entered puberty have serial gonadotrophin data available; two have increased LH and six increased FSH. Apart from patient 3, who underwent orchidectomy, all patients have normal testosterone levels and none have required hormone replacement therapy. The gonadotrophins in the five prepubertal subjects are normal. Serial gonadrophin levels for six boys with abnormal values are shown in Table 4 . Testicular volume data are shown in Table 4 . Smaller testicular volumes tended to be associated with more significant elevations of FSH. Table 3 Serial gonadotrophin values in girls (n = 
Pubertal development and endocrine function
IGF-I and thyroid function
IGF-I was tested on multiple occasions on the patients. The levels were low for age at some time in three of seven females tested and three of 13 males. However, these low levels tended to coincide with hypogonadism, and corrected with the onset of puberty, or appropriate replacement, so that by last follow-up only two of 13 boys tested and one of seven girls tested had low results. Thyroid function studies were available in 21 of 23 patients and were normal at most time points. Three patients had elevated TSH (values of 5.9, 6.8, 6.4, normal range 0.4-5.0 mU/ml) with normal free T 4 (10.1, 11.0, 11.2 with normal range 8-18 pmol/l) at one time point. In two of these the subsequent test was normal. In patient No. 1 this abnormal value was at his last testing at 10 years follow-up.
Discussion
The results of this study show that intensive chemotherapy followed by BUCY for AML does not impair growth. The pre-transplant period of intensive therapy is associated with little or no growth during the 6 months of this therapy, resulting in a reduction in HtSDS. However, patients at 5 years post BMT showed comparable HtSDS to that at diag-nosis. This supports and extends other reports. 4, 6, 7, 13, 14 Our limited final height data would also support BUCY having a minimal effect on growth.
It has been suggested that patients who experience high busulfan levels or high systemic exposure may have reduced growth. 4 This cannot be correct, as our unique use of a single daily dose of BU ensures that all patients experience very high peak levels, and consistent and high systemic exposure. 8 Together with the significant number of AML patients reported by Michel et al, 6 although with lower doses of BU, we would argue that BUCY has no significant effect on growth on children undergoing BMT. When children conditioned with BUCY exhibit inadequate growth post BMT other causes must be considered. These would include other treatment given, particularly cranial irradiation, 5, 7 and also factors related to the underlying disease, such as with thalassaemia 15 or the mucopolysaccharidoses. 16 The negative correlation between age at BMT and ⌬HtSDS at 1 year post BMT was accounted for by two of the youngest patients. Because of their age, errors in measurement are possible. We await further results on more of these very young patients before we can establish if this correlation is genuine or not.
Given the normal growth achieved by our patients, the finding of mainly transient low levels of IGF-I appears to be of little clinical significance.
Hypothyroidism is a frequent complication of TBI containing regimens. 6, 17 Three patients, all male, had an elevated TSH at one time point post BMT, which subsequently returned to normal in two of the cases. The third case, who had refused follow-up for many years, had his first testing of thyroid function at 10 years after BMT, when he had an elevated TSH but normal free T 4 . Although variability in the assay or another process could be causing hypothyroidism, the fact that he has the longest follow-up, and others have described hypothyroidism following BUCY, 6, 17 indicates that these patients must be considered to be at risk of hypothyroidism, and should continue to be monitored for this correctable problem.
The ultimate test of adequate gonadal function is fertility. As most children who were prepubertal at BMT are not at an age to consider pregnancy, indirect measures of gonadal dysfunction have to be adopted, such as elevated gonadotrophins. Certainly, it is well known that normal gonadotrophins do not predict normal gonadal function, especially in prepubertal subjects. In our series, all evaluable boys in our study entered puberty spontaneously. However, a significant proportion have elevated FSH (6/12), suggesting impaired spermatogenesis. The more elevated FSH values have been seen in the boys with reduced testicular volumes (Table 4 : patients Nos 8 and 5). Increased LH was only found in 2/12. None of the boys have required sex steroid replacement so far, having normal testosterone levels, but continued observation is required.
In contrast, five of six females have shown gonadal dysfunction post BMT and require sex steroid replacement; the sixth girl has elevated gonadotrophins but currently a normal oestradiol. In contrast to the boys, the most striking abnormality has been the early and persistent elevation of both FSH and LH. Two girls remain prepubertal (6.2 and Bone Marrow Transplantation 6.8 years at last follow-up); one has elevated FSH and the other has normal FSH and LH at last follow-up. The striking early elevation of gonadotrophins in the older girls suggests the outcome for the youngest girls may well be the same, but remains to be seen. In a series of 270 patients, younger age was associated with delayed time to onset of elevated gonadotrophins and the percentage with elevated gonadotrophins seemed to plateau at about 75%. However, only 20 of the patients were less than 20 years at BMT, and there was a range of diagnoses, some of whom received CY alone. 18 A number of recent reports have looked at the recovery of ovarian function following intensive chemotherapy. When girls receive intensive initial chemotherapy with subsequent high-dose therapy, ovarian dysfunction seems universal for those receiving a BU-containing regimen. In contrast, girls receiving similar intensive therapy followed by a non-BU-containing BMT therapy, are more likely to have normal gonadotrophins. 19, 20 This has been seen particularly with single agent melphalan. 20 Although the majority of children undergoing BMT for AML are conditioned with BUCY, good results have been reported with the use of melphalan alone. 21 If these results could be duplicated in a larger group of patients, preferably in a randomised study comparing BUCY with melphalan, then it would be reasonable to prefer the less toxic conditioning regimen. Girls who have received BUCY may be candidates for other therapies, such as ovarian tissue cryopreservation soon after the onset of puberty.
We have demonstrated that children with acute myeloid leukaemia who undergo BMT using BUCY do not experience significant growth impairment. Therefore, all children who receive BUCY without prior therapy should grow normally, unless this is impaired by the underlying disease for which the BMT is being performed. However, gonadal dysfunction is a prominent adverse effect in girls receiving this regimen. Whether this is due solely to the BUCY, or is also a reflection of the intensive prior therapy, is not certain, but evidence is starting to emerge that non-BU-containing regimens may be preferable, at least in girls.
